Companies will jointly develop BioNTech’s mRNA-based vaccine candidate BNT162 to prevent COVID-19 infection
Collaboration aims to accelerate global development of BNT162, leveraging expertise and resources of both companies.
Builds on 2018 agreement to jointly develop an mRNA-based influenza vaccine
United Arab Emirates, March 18, 2020 – Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together.
The collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162, which is expected to enter clinical testing by the end of April 2020. The rapid advancement of this collaboration builds on the research and development collaboration into which Pfizer and BioNTech entered in 2018 to develop mRNA-based vaccines for prevention of influenza.
“We are proud that our ongoing, successful relationship with BioNTech gives our companies the resiliency to mobilize our collective resources with extraordinary speed in the face of this worldwide challenge,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development & Medical, Pfizer. “We believe that by pairing Pfizer’s development, regulatory and commercial capabilities with BioNTech’s mRNA vaccine technology and expertise as one of the industry leaders, we are reinforcing our commitment to do everything we can to combat this escalating pandemic, as quickly as possible.”
“This is a global pandemic, which requires a global effort. In joining forces with our partner Pfizer, we believe we can accelerate our effort to bring a COVID-19 vaccine to people around the world who need it,” said Ugur Sahin, Co-Founder and CEO of BioNTech.
The companies expect to utilize multiple research and development sites from both companies, including in the United States and Germany, to house the activities identified by the collaboration agreement.
The companies will begin collaborating immediately. They will finalize details of the agreement regarding financial terms, and all activities related to development, manufacturing and potential commercialization over the next few weeks.
On March 13, 2020, Pfizer issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Pfizer Disclosure Notice:
The information contained in this release is as of March 17, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, BioNTech’s potential COVID-19 mRNA vaccine, BNT162, a letter of intent regarding the co-development and co-commercialization (excluding China) by Pfizer and BioNTech of BNT162 and a Material Transfer and Collaboration Agreement, including their potential benefits, and the expected timing of a Phase 1 trial, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, whether and when a definitive agreement will be reached for the co-development and co-commercialization by Pfizer and BioNTech of BNT162 ; uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when any biologics license applications may be filed in any other jurisdictions for BNT162 or any other vaccine candidates under the collaboration; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether BNT162 will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of BNT162; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities regarding BNT162 and uncertainties regarding the commercial impact of any such recommendations; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun, and Pfizer. For more information, please visit www.BioNTech.de.
This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, the ability of BioNTech to develop and commercialize a vaccine for COVID-19, BioNTech’s potential COVID-19 mRNA vaccine, BNT162, a letter of intent regarding the co-development and co-commercialization (excluding China) by Pfizer and BionNTech of BNT162 and a Material Transfer and Collaboration Agreement, including their potential benefits, and the expected timing of a Phase 1 trial of BNT162. Any forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: competition to create a vaccine for Covid-19 and potential difficulties. For a discussion of these and other risks and uncertainties, see the section entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in BioNTech’s Registration Statement on Form F-1 filed with the SEC on September 9, 2019, as amended, which has been filed with the SEC and is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.
Anand George Zachariah
+971 4 330 4010 ext.455 or +971 55 3766809
HRSE (HR Summit & Expo) GOES VIRTUAL FOR 2020!
- After 16 successful years, the region’s biggest HR event announces that they will go virtual in 2020
- Bringing together 4,000+ Regional & Global HR professionals who will be joining the event virtually
Dubai, UAE, 23 August 2020: HRSE (HR Summit & Expo) 2020 announced today that the seventeenth edition of its annual HR event will go virtual this year.
A first of its kind for the region, HRSE (HR Summit & Expo) 2020 can be experienced from people’s laptops, mobiles, or tablets, from 15-18 November. Speaking about the event Tina Newton, Program Manager for HRSE (HR Summit & Expo) 2020, said “In our efforts to bring our regional and Global HR community together to tackle some of the biggest workplace challenges ever faced, we have decided to make HRSE (HR Summit & Expo) 2020 a completely virtual event. This year’s summit experience will provide an unrivalled opportunity for HR leaders to experience four transformative days of knowledge sharing.”
Focused on the theme ‘New World. New Ways. New Thinking’, the agenda will cover all the hard-hitting issues keeping HR at night – skills needed in the new normal New age leadership, Engagement and Productivity, Diversity & Inclusion, Digital HR Transformation, Digital Learning & Development and many more. The summit also features 12 certified virtual HR Workshops run in association with partners such as the Society for Human Resources Management (SHRM) and the Association for Talent Development (ATD).
The show is also known for its stellar line-up of headline speakers such as Malcolm Gladwell, Dave Ulrich, Kory Kogan, Marcus Buckingham, Fons Trompenaars, David Shing, Mark Pollock and many more who have been a part of the event before. This year, HRSE is headlined by one of the most widely recognized figures in science in the world today – Dr. Michio Kaku, a Top Theoretical Physicist, Best-Selling Author and Populizer of Science & STEM.
Sharing his views on the future of work in a post-COVID world, Dr. Michio said, “AI and high tech will crush the coronavirus. The coronavirus, instead of disrupting the march toward a digital world, has actually accelerated it, vastly strengthening the current revolution towards a digital, virtual world. Furthermore, AI and high technology will actually conquer the virus, by rapidly locating outbreaks and hotspots of the virus as they occur, identifying and isolating super spreaders, decoding the genetic weak spots of the virus, producing a safe vaccine in record time, and eventually crushing the pandemic. For the first time in human history, AI and high technology will allow us to vanquish this ancient but deadly enemy.’’
HRSE (HR Summit & Expo) 2020 is renowned for delivering an industry-leading annual HR event bringing together over 4,000 HR professionals from across the region. The event also brings together 50+ regional and international HR Solution Providers showcasing their services at the event, including: Wellness Partner & Virtual Platform Sponsor, AXA; Headline Sponsor, The Wharton School; Platinum Sponsor, Cigna Corporation;; Silver Sponsor, Akrivia Automation; Learning Sponsors, ICS Learn and Wide Impact.
For HR professionals looking to stay on top of the latest industry trends, share knowledge and learn about latest developments in technology solutions and discover new ways adopted by other leading organizations that has undergone transformation journeys, HRSE (HR Summit & Expo) 2020 is a must-attend event.
The HRSE (HR Summit & Expo) is the region’s largest HR and people management event hosting 4,000+ [KL1] professionals and over 50[KL2] solutions and service providers. The main conference addresses the profession’s pressing challenges and discusses the latest trends through a comprehensively designed agenda with real life examples and practical case studies. HRSE (HR Summit & Expo) is the platform where HR, technology and the new world of work join forces.
About Informa Connect:
Informa Connect is a division of Informa plc, a global business that is listed on the London Stock Exchange and a member of the FTSE 100. Informa plc. has a network of trusted brands in specialist markets across more than 30 countries with 11,000+ colleagues. Informa Connect is a live events and digital platform specialist connecting individuals and professionals with knowledge, ideas and opportunities. Our purpose is to champion the specialist. Through hundreds of powerful brands, we work with businesses and professionals in specialist markets, providing the connections, intelligence and opportunities that help customers grow, do business, make breakthroughs and take better informed decisions. Operating major branded events in Finance, Biotech & Pharma and in a number of other specialist markets and connect communities online year-round.
For more information, please contact:
Marketing Manager | Informa Connect
The Compensation and Benefits Forum- KSA 14th & 15th September 2020 A Post-Pandemic Outlook for 2021 And Beyond
Written By: Mariham Magdy
DIVE INTO WORLD-CLASS INSIGHTS IN TOTAL REWARDS FROM THE COMFORT OF YOUR HOME, a new concept has been adopted and excellently implemented by Informa Middle East at The Compensation and Benefits Forum KSA that, took place on, 14th – 15th September 20, with the theme of “Developing Total Rewards to Engage, Attract, and Retain Top Talent in KSA”.
The event was attended by more than 100 HR Professionals from different organizations and industries in KSA.
This year’s Compensation & Benefits Forum KSA has been redesigned to address the latest C&B updates owing to COVID-19 to help attendees to stay up-to-date and drive business impact.
Informa Connect Middle East, has re-envisioned this year’s forum and transformed it into a 100% virtual learning and networking experience.
This year event included a characterized line-up of 20+ inspirational speakers; included:
Robert Mosley, Global Renumeration Expert & HR Consultant, CEO, Lemon PIP Consulting Limited.
In addition to Peter Lemperis, Global Director of Compensation, Benefits and Mobility, Aramex, Luca Marrocco, Total Rewards Manager, Talabat, Sanjeev Sahgal, Head HR Strategy & Agile HR the World Bank, Waddah Turki, Country Talent Manager, IKEA KSA, Mohammed Abdul Quddus, Head of C&B MENA, Kuwait Food Company, Hayfa Abuzabibah, Group HR Director, Al Dabbagh Group, and more.
Among the most important topics discussed throughout the conference days were:
- How Talabat are utilising technology to prepare for the digital future of total rewards?
- How leading organisations benchmark using data analysis tools and techniques to ensure fair pay practices.
- The 10 most common errors when designing successful incentive plans and how to avoid them
- Addressing the importance of creating an enabling culture for mental health and well-being
- Linking performance reviews to your reward strategy helps you create a pay-for performance culture
The event included an exhibition showing case of rewards solutions to KSA’s HR Professionals.
Three workshops led by the Global Remuneration Expert & HR Consultant/ CEO of Lemon Pip Consulting Limited, including: Workshop A, Job Evaluation, Grades & Agile Grading Workshop C, Remuneration Strategy – Benchmarking-Design, took place on the 16th of September 20, and Workshop D, Performance Management and Pay-for-Performance, taking place on 17th of September 20.
In addition to a special Workshop provided by Dianne Auld Excel for Reward Expert at Auld Compensation Consulting, about Intermediate Excel Skills and Dashboards for compensation professionals, took place on 15th of September 20.
Worth mentioning; that HR Revolution Middle East Magazine, was among the media partners for the event this year.
For more information: www.informa-mea.com
KNect365 / Informa operate at the heart of the Knowledge and Information Economy. It is one of the world’s leading business intelligence, academic publishing, knowledge and events businesses. With more than 6,500 employees globally, it has a presence in all major geographies, including North America, South America, Asia, Europe, theMiddle East and Africa.
For more information: www.hrrevolution.me
HR Revolution Middle East was founded in Egypt since 2015 by founded by Award Winning Author & HR professional Mahmoud Mansi – with a dedicated mission to highlight the roles of HR & Business Professionals in the media.
Winners Announced in the Fifth Annual Stevie® Awards for Great Employers Top Winners Include IBM Corporation and Tata Consultancy
Winners in the 2020 (fifth annual) Stevie® Awards for Great Employers, an international competition, were announced today. The awards recognize the world’s best employers and the human resources professionals, teams, achievements, and HR-related products and suppliers who help to create and drive great places to work.
Among the organizations with the most Stevie-winning nominations are IBM Corporation, worldwide (18), Tata Consultancy Group (18), Cisco (10), Bank of America (nine), and Cathay United Bank, Dell Technologies, DHL Supply Chain, Globe Telecom, Pan American Energy, and QNB FINANSBANK, each with five.
For a full list of winners by category, visit www.StevieAwards.com/HR.
All Gold, Silver, and Bronze Stevie Award winners will be celebrated at a virtual awards ceremony on November 5. Tickets are now on sale.
More than 700 nominations from organizations from 23 nations were evaluated in this year’s competition. Winners were determined by the average scores of more than 90 professionals worldwide, acting as judges.
The Stevie Awards for Great Employers recognize achievement in many facets of the workplace. Categories include:
Employer of the Year
HR Individual Awards
HR Team Categories
Solution Provider Awards
More than 50 New Product & Service Categories
Stevie Award placements in the 31 Employer of the Year categories were determined by a unique blending of the ratings of professionals and the votes of the general public.
More than 30,000 votes were cast by members of the public for their favorite employer this year.
The awards are presented by the Stevie Awards, which organizes several of the world’s leading business awards shows including the prestigious International Business Awards® and American Business Awards®.
About the Stevie Awards
Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, and the Stevie Awards for Sales & Customer Service.
Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about
the Stevie Awards at http://www.StevieAwards.com.
HR Revolution Middle East Magazine is proud to be the main Media Partner for the Stevie Awards for Great Employers
Q&A with Yasmine Yehia | MEA Employer Branding Manager at Schneider Electric, Life Coach & Consultant
Interviewer: Mahmoud Mansi “To be able to have a strong brand, you need to start from within – you need...
Stevie Awards Winners’ Articles Series – Eng. Abeer Mahmoud Ramadna
“Continuous Learning, adopting innovation & creativity and teamwork are among the guiding principles of success and excellence in the government...
مقابلة صحفية مع إيناس عبدالقادر – مهندسة نسيج ومتحدثة في مؤتمر تيدكس وادمدني بالسودان
صحافة: محمود منسي ثورة الموارد البشرية: إيناس لديك العديد من الخبرات في مجالات مختلفة، هل يمكن أن تعطينا نبذة عن...
Stevie Awards Winners’ Articles Series – Asiacell
“Winning such an award requires hard work and we encourage other companies to focus on their customers and local communities...
Q&A with Germeen El Manadily; TV Presenter | Publisher | Digital Marketing Expert | TEDx Speaker
Interviewer: Mahmoud Mansi “After the COVID-19 Pandemic, the world came to the realization that social media has a huge influence...
Interview with Stephanie Runyan, PHR, the Director of Learning for the HR Certification Institute
“HR professionals must be prepared for anything. The roles of HR professionals continually change, there will be a continued need...
Q&A with Mahmoud Sami Ramadan – Digital Advertising Specialist, Dubai
Interviewer: Mahmoud Mansi “I am going around and discovering and jumping from one field to another, to be able to...
Qisaty Project & Developing Talent in Children with Special Needs in Egypt
Edited By: Mahmoud Mansi Qisaty Project – founded by Mona Lamloum – was launched on 26th December 2019 to support...
Stevie Awards Winners’ Articles Series – Kuveyt Türk Participation Bank Case
“Each institution’s culture is unique. Employee culture and corporate culture should create a common blend” Nomination: Stevie Internal Communication Bronze...
Q&A with Sherihan Elkamash; Researcher at the Center of Strategic Studies, Bibliotheca Alexandrina & Charity Activist
Interviewer: Mahmoud Mansi “I am always trying to not lead members, but inspire them and gain their trust by encouraging...
- Arbeit Tipps
- Business Poetry
- Careers in Alex
- Civil Work
- Criticize HR
- Employee Diary
- HR Feminism
- HR Fossils
- Job Opportunities
- Kritisieren HR
- Personal Branding
- Press Releases
- Work Tips
- حفريات موارد بشرية
- حقوق المرأة والموارد البشرية
- مقابلات شخصية
- نصائح عمل
- نقد الموارد البشرية
- نقد سينمائي
Interviews2 weeks ago
Q&A with Germeen El Manadily; TV Presenter | Publisher | Digital Marketing Expert | TEDx Speaker
Articles5 years ago
10 Reasons “The Intern” Is a To-Watch-and-Learn Movie
Articles4 years ago
Challenge Stressors Versus Hindrance Stressors, and Resources to Overcome Stressors
Interviews5 years ago
حوار صحفي مع الكاتبة الشابة والمهندسة نوران السقيلي
Interviews2 weeks ago
Q&A with Mahmoud Sami Ramadan – Digital Advertising Specialist, Dubai
Articles2 weeks ago
Stevie Awards Winners’ Articles Series – Asiacell
Movies5 years ago
Minions as An Inspiration for Workers!
Articles1 year ago
6 Personality Traits that Tell if you are a “Considerate” Employee